![Shachar Shlosberger](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 5 108 $ al 30/06/2026
Shachar Shlosberger is currently the Chief Financial Officer at Enlivex Therapeutics Ltd. She previously worked as the Finance Director at Prolor Biotech Ltd. Shlosberger holds a Master's in Business Administration from The College of Management Academic Studies.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
ENLIVEX LTD. 0 % | 18/03/2026 | 9.288 ( 0 % ) | 5 108 $ | 30/06/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| ENLIVEX | Director Financiero/CFO | 01/01/2016 |
| Empresas | Cargo | Fin |
|---|---|---|
Prolor Biotech Ltd.
 Prolor Biotech Ltd. BiotechnologyHealth Technology Develops proprietary versions of already-approved therapeutic proteins | Director Financiero/CFO | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 3 |
|---|---|
The College of Management Academic Studies
 The College of Management Academic Studies Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Prolor Biotech Ltd.
Prolor Biotech Ltd. BiotechnologyHealth Technology Develops proprietary versions of already-approved therapeutic proteins | Health Technology |
Enlivex Therapeutics Ltd.
 Enlivex Therapeutics Ltd. BiotechnologyHealth Technology Develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
